Sica, Antonello and Sagnelli, Caterina and Casale, Beniamino and Svanera, Gino and Creta, Massimiliano and Calogero, Armando and Franco, Renato and Sagnelli, Evangelista and Ronchi, Andrea (2021) How Fear of COVID-19 Can Affect Treatment Choices for Anaplastic Large Cell Lymphomas ALK+ Therapy: A Case Report. Healthcare, 9 (2). p. 135. ISSN 2227-9032
healthcare-09-00135-v2.pdf - Published Version
Download (580kB)
Abstract
Background: The t (2; 5) chromosomal rearrangement of the ALK gene with nucleophosmin 1 gene (NPM1), resulting in an NPM1–ALK fusion, was first demonstrated in 1994 in anaplastic large cell lymphoma, (ALCL), a T-cell lymphoma responsive to cyclophosphamide, abriblastine, vincristine and prednisone in approximately 80% of cases; refractory cases usually respond favorably to brentuximab vedotin. These treatments are regarded as a bridge to allogeneic hematopoietic stem cell transplantation (allo-SCT). Nowadays, transplant procedures and the monitoring of chemotherapy patients proceed very slowly because the SARS-CoV-2 pandemic has heavily clogged the hospitals in all countries. Results: A 40-year-old Caucasian woman was first seen at our clinical center in June 2020. She had ALCL ALK+, a history of failure to two previous therapeutic lines and was in complete remission after 12 courses of brentuximab, still pending allo-SCT after two failed donor selections. Facing a new therapeutic failure, we requested and obtained authorization from the Italian drug regulatory agency to administer 250 mg of crizotinib twice a day, a drug incomprehensibly not registered for ALCL ALK +. Conclusions: The response to crizotinib was optimal since no adverse event occurred, and CT-PET scans persisted negative; this drug has proved to be a valid bridge to allo-SCT.
Item Type: | Article |
---|---|
Subjects: | Journal Eprints > Medical Science |
Depositing User: | Managing Editor |
Date Deposited: | 24 Jan 2023 05:37 |
Last Modified: | 27 Feb 2024 04:18 |
URI: | http://repository.journal4submission.com/id/eprint/709 |